Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study
Background Antazoline mesylate represents an antihistamine capable of rapid and safe cardioversion of atrial fibrillation, yet evidence concerning its efficacy in comparison to other medications is insufficient. The study aimed to evaluate the success rate and safety of pharmacological cardioversion...
Main Authors: | Maciej T. Wybraniec, Wojciech Wróbel, Katarzyna Wilkosz, Karolina Wrona, Karolina Bula, Katarzyna Mizia‐Stec |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-10-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.118.010153 |
Similar Items
-
Comparison of efficacy of pharmacological cardioversion
with antazoline and propafenone versus electrical
cardioversion in atrial fibrillation during cryoablation
by: Konrad Klocek, et al.
Published: (2024-03-01) -
Clinical Characteristics of Atrial Flutter and Its Response to Pharmacological Cardioversion with Amiodarone in Comparison to Atrial Fibrillation
by: Maciej T. Wybraniec, et al.
Published: (2023-06-01) -
Systematic review of the safety and efficacy of antazoline in the treatment of atrial fibrillation.
by: Raghad Aldulaymi, et al.
Published: (2022-01-01) -
Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)
by: Farkowski Michal M, et al.
Published: (2012-09-01) -
Efficacy of Electrical Cardioversion in Relation to Occurrence and Type of Functional Mitral Regurgitation in Patients with Atrial Fibrillation
by: Konrad Klocek, et al.
Published: (2022-04-01)